Ingelheim Pharmaceuticals Proprietary Ltd.

Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board.
Business Wire; 12/7/2009; 848 words; ...Searle & Co., Ltd. and was a Lecturer...to advance its proprietary products and...Limited, a generic pharmaceutical company, QLT...biotherapeutics using its proprietary Protein Design...Pfizer, CSL Ltd., Boehringer Ingelheim, and Human Genome...

Xencor Appoints Jeffrey V. Ravetch of the Rockefeller University to its Scientific Advisory Board.
Clinical Trials Week; 9/14/2009; 1106 words; ...biotherapeutics using its proprietary Protein Design Automation...Merck, Pfizer, CSL Ltd., Boehringer Ingelheim, MedImmune and Human...applying its suite of proprietary antibody Fc domains...Trials, Genetics, Pharmaceutical, Research, Science...

Xencor Presents Preliminary Phase I Data on XmAb[R]2513 Antibody for Lymphomas at 2009 American Society of Clinical Oncology Annual Meeting.
Blood Weekly; 6/18/2009; 1579 words; ...from Xencor's proprietary antibody engineering...biotherapeutics using its proprietary Protein Design...Pfizer, CSL Ltd., Boehringer Ingelheim, MedImmune...its suite of proprietary antibody Fc...Oncology, Pharmaceutical, Other Health...

The Asian Cardiovascular Market Outlook to 2014: Regional and Therapeutic Analysis, Pipeline Impact and Growth Opportunities.
M2 Presswire; 4/22/2009; 719 words; ...2009 M2 COMMUNICATIONS LTD RDATE:22042009 Dublin...and consequently the pharmaceutical sector. The market...expiries minimally affect proprietary brand growth dynamics...Dalcetrapib - Boehringer Ingelheim For more information...M2 Communications Ltd disclaims all liability...

Xencor Licenses Xtend[TM] Antibody Half-Life Prolongation Platform to Merck & Co., Inc.
Biotech Week; 4/8/2009; 1034 words; ...enhance the pharmaceutical properties...Xencor's proprietary antibody...Genentech, CSL Ltd., Boehringer Ingelheim, MedImmune...Company Inc., Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Therapy...